Delaware district court rules in favor of acadia on formulation patent construction (markman) claims regarding nuplazid® (pimavanserin)

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the u.s. district court for the district of delaware has issued a claim construction order in favor of acadia regarding its ‘721 formulation patent for nuplazid® (pimavanserin), acadia's drug for the treatment of parkinson's disease psychosis. in today's order, the court ruled in favor of acadia on all of the disputed claim construction points. in the order, the court adopted acadia's interpretation of k.
ACAD Ratings Summary
ACAD Quant Ranking